Borderline Personality Disorder
Clinical Snapshot
Borderline personality disorder (BPD) is a pervasive, long-standing pattern of instability in emotion regulation, interpersonal relationships, self-image, and impulse control, present by early adulthood and evident across a variety of personal and social contexts — not confined to a single relationship or situation. At its core, BPD is a disorder of emotion dysregulation: intense, rapidly shifting emotional states that are genuinely harder to control and slower to settle than in most people, arising from a real interaction between biological temperament and developmental environment (see Risk Factors). Framing BPD this way — as a real, biologically grounded disorder rather than a label for a "difficult" or "manipulative" patient — is itself one of the most clinically important things a pharmacist can do, and directly shapes how a patient engages with care.
BPD affects an estimated 1.6% of community adults over a 12-month period (lifetime prevalence up to about 5.9%), but is far more concentrated in clinical settings: roughly 6% of primary care patients, about 10% of psychiatric outpatients, and about 20% of psychiatric inpatients meet criteria.[1] Two points anchor everything else in this chapter. First, structured, evidence-based psychotherapy — dialectical behavior therapy (DBT) foremost — is the only first-line treatment, endorsed by every current major guideline.[2][3][4] Second, and just as important for a pharmacist to know explicitly: no medication is approved by Health Canada or the FDA for the treatment of BPD itself, and current guidance specifically recommends against using drug treatment as primary therapy or for individual symptoms/behaviours associated with the disorder — pharmacotherapy has a real but strictly adjunctive role, reserved for specific comorbid symptom clusters.[2][5] This population also carries a genuinely elevated risk of self-harm and completed suicide, which every pharmacist interacting with these patients needs to be prepared to recognize and escalate appropriately (see Red Flags).[6]
Recognize the Condition
DSM-5-TR diagnostic pattern
A pervasive pattern of instability in interpersonal relationships, self-image, and affect, together with marked impulsivity, beginning by early adulthood and present in a variety of contexts, indicated by 5 or more of the following 9 features.[1]
| Feature | What it looks like clinically |
|---|---|
| 1. Frantic efforts to avoid abandonment | Real or even imagined separation or rejection triggers an intense, often disproportionate reaction — not limited to actual abandonment. |
| 2. Unstable, intense relationships | A pattern of alternating between idealizing and devaluing the same person ("splitting") — a partner, friend, or clinician can be seen as entirely wonderful one day and entirely terrible the next. |
| 3. Identity disturbance | A markedly and persistently unstable self-image or sense of self — goals, values, and even sexual identity can shift substantially over time. |
| 4. Impulsivity in at least 2 potentially self-damaging areas | Spending, unsafe sex, substance use, reckless driving, or binge eating, for example — excluding the suicidal/self-mutilating behaviour covered separately below. |
| 5. Recurrent suicidal behaviour, gestures, or threats, or self-mutilating behaviour | See Red Flags — this is a core diagnostic feature, not a separate or incidental complication. |
| 6. Affective instability from marked mood reactivity | Intense episodic dysphoria, irritability, or anxiety, usually lasting hours and rarely more than a few days — a key differentiator from bipolar disorder (see Assessment & Diagnosis). |
| 7. Chronic feelings of emptiness | A persistent, often distressing sense of inner emptiness or boredom, distinct from situational low mood. |
| 8. Inappropriate, intense anger or difficulty controlling anger | Frequent displays of temper, recurrent physical fights, or anger disproportionate to the trigger. |
| 9. Transient, stress-related paranoid ideation or severe dissociative symptoms | Brief, stress-triggered episodes rather than a persistent psychotic or dissociative disorder — typically resolves as the acute stressor and its associated arousal subside. |
The biosocial model
The best-supported etiologic model frames BPD as arising from an ongoing transaction between an inborn emotional vulnerability and an invalidating developmental environment.[7] Emotional vulnerability means a biological predisposition to unusually intense, easily triggered negative emotion with a slow return to baseline. An invalidating environment is one that persistently dismisses, punishes, or trivializes a child's emotional expression — telling a distressed child their reaction is wrong, excessive, or attention-seeking, rather than helping them learn to identify and regulate it. Neither factor alone reliably produces BPD; it is the ongoing interaction between the two across development that does; a child with the same temperament raised in a validating, emotionally responsive environment may never develop the disorder, and not every patient with BPD has an identifiable trauma history.[7]
Course over time — a genuinely hopeful point
BPD was once assumed to be a lifelong, essentially untreatable condition. Long-term prospective follow-up data have overturned that assumption: about half of patients achieve full recovery (symptomatic remission plus good social and vocational functioning) within 10 years, and roughly 93% achieve at least a 2-year symptomatic remission — and once attained, this remission tends to be genuinely stable rather than a temporary lull.[8] This is an important message to reinforce with patients directly: BPD responds to appropriate treatment, and the trajectory is not fixed.
Epidemiology and associated features
BPD is diagnosed roughly 3 times more often in women than men in clinical settings, but structured community studies suggest a more equal sex distribution — a gap that likely reflects referral and ascertainment patterns rather than a true difference in who develops the disorder.[1] Symptoms most often become clinically prominent in adolescence or young adulthood. Comorbidity is the rule rather than the exception: mood disorders (major depressive disorder and bipolar disorder), anxiety disorders, PTSD, eating disorders (particularly bulimia nervosa), substance use disorders (present in roughly half of patients), and other personality disorders all occur at substantially higher rates in patients with BPD than in the general population.[1]
Risk Factors
- Genetic and temperamental vulnerability — twin and family studies suggest substantial heritability (commonly estimated around 40-50%), expressed as an inborn tendency toward high negative emotionality, impulsivity, and heightened, slow-to-resolve emotional reactivity.[7]
- An invalidating developmental environment — a caregiving environment that persistently dismisses, punishes, or trivializes a child's emotional experience, rather than helping the child learn to identify and regulate it; this is the environmental half of the biosocial model and does not require overt abuse to have this effect.[7]
- Childhood trauma — physical, sexual, or emotional abuse, and neglect, are reported at substantially higher rates in patients with BPD than in the general population, though a meaningful proportion of patients have no identifiable trauma history — trauma is a strong risk factor, not a diagnostic requirement.[7]
- Early insecure or disorganized attachment — an inconsistent or frightening early caregiving relationship is a recognized contributor to the developmental pathway described above.
- A family history of BPD or other significant psychiatric illness — including mood disorders and substance use disorders, consistent with both a shared genetic vulnerability and a shared environmental pathway.
- Comorbid ADHD or other impulse-control difficulty in childhood — an early impulsivity/emotional-reactivity phenotype is one of the probable developmental pathways described in the biosocial model.[7]
These factors are probabilistic, not deterministic — the biosocial model explicitly frames BPD as arising from an interaction of vulnerability and environment over time, not from any single risk factor in isolation, and patients should never be assumed to have a specific history (particularly abuse) simply because of the diagnosis.[7]
Red Flags & Refer
Self-harm and suicide risk are core, expected features of this disorder — not an unusual complication — and pharmacists interacting with this population need to be genuinely prepared to recognize and escalate them. Roughly three-quarters of patients with BPD attempt suicide at some point, and approximately 8-10% eventually die by suicide — among the highest rates of any psychiatric diagnosis.[6] The following changes the plan from routine support to immediate escalation:
- Active suicidal intent, a specific plan, or access to means — treat as an emergency; activate the local crisis pathway (crisis line, mobile crisis team, or emergency department) immediately. Do not attempt to manage active suicidality within a routine pharmacy encounter.
- A significant change or escalation from the patient's known baseline pattern of self-harm — increased frequency, increased lethality/method change, or self-harm occurring for the first time — is a meaningfully different risk signal from a chronic, stable pattern and warrants urgent reassessment rather than routine follow-up.
- Comorbid substance intoxication alongside distress or self-harm disclosure — intoxication independently increases impulsivity and completed-suicide risk and should lower the threshold for escalation.
- A first presentation of significant self-harm in a patient with no established mental health care team — arrange urgent connection to care rather than routine referral.
- Signs of psychotic decompensation that are not clearly transient and stress-related — persistent (rather than brief, stress-triggered) paranoid ideation, hallucinations, or severe dissociation warrants reassessment of the diagnosis and urgent psychiatric evaluation.
- Evidence of ongoing abuse, intimate partner violence, or an unsafe living situation — assess safety directly and connect to appropriate services.
- New or worsening symptoms in the postpartum period, with any concern for infant safety — escalate urgently; this period carries genuinely elevated risk (see Special Populations).
Do not dismiss repeated self-harm disclosures as "attention-seeking." This is a well-documented, harmful form of clinician stigma toward this specific population — every disclosure is a genuine clinical symptom that deserves a compassionate, structured response, delivered through the pharmacy's own escalation protocol, not a judgment about the patient's motives.[9][6]
Assessment & Diagnosis
Screening
The McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) is a widely used 10-item yes/no self-report tool that maps directly onto the 9 DSM-5-TR criteria above (affective instability, anger, impulsivity, abandonment fears, relationship instability, self-harm/suicidality, emptiness, identity disturbance, and stress-related dissociation/paranoia, with 2 items covering the impulsivity criterion). It is presented here as a teaching reference to the domains it screens, not as a live interactive calculator or a diagnostic instrument in its own right — a positive screen supports referral for formal assessment, not a diagnosis on its own.
Formal diagnosis
A confirmed BPD diagnosis requires a structured clinical assessment — ideally a semi-structured diagnostic interview such as the SCID-5-PD — performed by a clinician trained in personality disorder assessment. This is not something to be established from a screening tool or a single encounter, and it is not a pharmacist's role to diagnose it; the pharmacist's role is pattern recognition (the features in Recognize the Condition), appropriate referral for formal assessment when the pattern is suspected but undiagnosed, and safe, informed care once a diagnosis is established.
Differentiating BPD from commonly confused conditions
| Condition | Key differentiating features from BPD |
|---|---|
| Bipolar I or II disorder | Bipolar mood episodes are sustained (days to weeks) and relatively autonomous from interpersonal triggers; BPD mood shifts are typically brief (hours, rarely more than a few days) and reactive to interpersonal events. Relying on the phrase "mood swings" alone, without assessing episode duration and trigger pattern, is a common source of misdiagnosis in both directions.[10] |
| Complex PTSD (ICD-11) | Both conditions can follow childhood trauma and share affective dysregulation, but complex PTSD's relational pattern is characterized by avoidance and difficulty trusting others, while BPD's relational pattern is characterized by active, volatile swings between closeness and conflict (splitting). Self-concept in complex PTSD is persistently and stably negative; in BPD it fluctuates, often tracking the current idealization/devaluation of a relationship. Complex PTSD also requires a clear qualifying trauma history and core PTSD re-experiencing/avoidance/threat symptoms, which are not required for BPD.[11] |
| Narcissistic personality disorder | Both can show anger and interpersonal conflict, but narcissistic PD's self-image is grandiose and relatively stable rather than fluctuating, and abandonment is met with indifference or contempt rather than the frantic distress typical of BPD. |
| Histrionic personality disorder | Both show intense, attention-seeking interpersonal styles, but histrionic PD lacks the chronic emptiness, identity disturbance, and prominent self-harm/suicidality core to BPD. |
| Antisocial personality disorder | Both can show impulsivity and anger, but antisocial PD's behaviour is oriented around disregard for others' rights and a lack of remorse, rather than the fear of abandonment and identity instability that drive BPD's interpersonal pattern. |
| ADHD | Both feature impulsivity, but ADHD's core deficit is attention/executive function present since early childhood across settings, without the affective instability, chronic emptiness, or identity disturbance of BPD — though the two conditions frequently co-occur. |
| Major depressive disorder | Depression is episodic, with a relatively stable, pervasively low mood across the episode; BPD's dysphoria is characteristically reactive and rapidly shifting, embedded within the broader interpersonal/identity pattern rather than a discrete episode. |
Investigations
There is no diagnostic laboratory test for BPD. A reasonable baseline work-up — thyroid function, CBC, and a substance-use history/screen — is appropriate to identify an organic or substance-induced contributor to mood or behavioural instability, particularly at first presentation or when the pattern is atypical, but this is adjunctive to the clinical assessment above, not diagnostic for BPD itself.
Treatment Targets
- Reduce self-harm and suicidal behaviour, and keep the patient safe — the highest-priority target given the mortality risk in this population.[6]
- Improve the capacity to regulate intense emotion — the central mechanism this disorder disrupts, and the core target of every evidence-based psychotherapy covered in this chapter.
- Reduce other impulsive, self-damaging behaviours (substance use, unsafe sex, reckless spending or driving, binge eating).
- Improve interpersonal functioning and relationship stability, including reducing the frequency and intensity of the idealization-devaluation pattern.
- Build a more stable, coherent sense of identity and self-image over time.
- Treat comorbid conditions (mood disorders, anxiety disorders, PTSD, eating disorders, substance use disorders) on their own terms rather than assuming every symptom is "the personality disorder."
- Avoid iatrogenic harm from the care system itself — specifically, reflexive polypharmacy and crisis-only engagement without a coordinated, longitudinal plan (see Choose Initial Treatment and Common Errors).
- Build durable self-management and emotion-regulation skills the patient can use independently, rather than creating dependence on crisis-driven contact alone.
- Set the expectation explicitly: full symptomatic remission is a realistic, evidence-supported outcome for most patients over time, not a false promise.[8]
Choose Initial Treatment
Psychotherapy is the only first-line treatment
1st line, for every patient refer for structured, evidence-based psychotherapy — this is the only treatment with a genuine primary evidence base for BPD, endorsed explicitly by both NICE and the APA.[2][3] Dialectical behavior therapy (DBT) has the largest and most consistent evidence base, including reductions in self-harm and suicide attempts, and is the preferred first choice where available.[4] Mentalization-based therapy (MBT), schema-focused therapy, and General Psychiatric Management (GPM) are all also evidence-supported and reasonable alternatives — a 2020 Cochrane review found that structured ("bona fide") psychotherapies as a group produce a real, moderate benefit over usual care and over unstructured/non-manualized therapy, though the overall certainty of evidence for any one specific modality outperforming another head-to-head remains low, and access, not a meaningful difference in expected benefit, should generally drive which specific modality a patient starts.[4] See Non-Pharmacologic Treatment for what each modality actually involves.
No medication is approved or curative — pharmacotherapy is adjunctive only
No medication is approved by Health Canada or the FDA for the treatment of BPD itself, and current guidance explicitly recommends against using drug treatment as primary therapy, or specifically to treat the individual symptoms or behaviours associated with the disorder as a whole.[2] A 2022 Cochrane review of pharmacological interventions found no clear, consistent evidence that any drug class meaningfully improves overall BPD severity, and rated the certainty of evidence for most individual outcomes as low to very low.[5] This is a genuinely important point for pharmacist counselling: medication is never a substitute for structured psychotherapy in this disorder, and starting or continuing a medication should never be allowed to delay or replace a referral for psychotherapy.
When adjunctive pharmacotherapy is reasonable
Reserve pharmacotherapy for specific, identifiable target symptom clusters that persist despite an adequate trial of structured psychotherapy, or as a time-limited bridge while access to psychotherapy is arranged — never as routine or default treatment. Every trial should have an explicit target symptom, a defined reassessment date, and a plan to stop if that specific target does not improve (see Monitoring & Follow-Up and Common Errors).[5]
Affective dysregulation / comorbid mood or anxiety symptoms a trial of an SSRI is reasonable when a comorbid depressive or anxiety disorder is present or clearly suspected — evidence for BPD-specific mood-lability benefit alone is weak and inconsistent, so treat this as managing the comorbidity, not as treating BPD itself.[5]
Impulsivity / behavioural dyscontrol / anger a mood stabilizer (lamotrigine, topiramate, or divalproex) has modest, inconsistent trial evidence for this specific symptom cluster — evidence quality is low, and at least one large, more rigorous trial found no benefit for lamotrigine over placebo, so set expectations accordingly and reassess objectively.[5]
Transient cognitive-perceptual or psychotic-like symptoms, or severe affective instability a low-dose atypical antipsychotic (aripiprazole, olanzapine, or quetiapine) has modest short-term trial evidence — reserve for this specific indication, use the lowest effective dose, and reassess regularly given the metabolic monitoring burden (see Drug Tables).[5]
Avoid benzodiazepines real risk of disinhibition and paradoxical aggression in this population, dependence risk with an already elevated impulsivity/substance-use burden, and no evidence of core-symptom benefit — avoid routine or ongoing use.[2][5]
Avoid reflexive polypharmacy stacking multiple unproven psychotropic agents over time, without a specific target symptom or a plan to stop an ineffective one, is a well-recognized and avoidable problem in BPD care — every agent needs its own justification and its own stopping rule.[5][2]
Non-Pharmacologic Treatment
Dialectical behavior therapy (DBT)
Developed specifically for BPD, DBT has the strongest evidence base of any single intervention, including genuine reductions in self-harm and suicide attempts across randomized trials.[4] It combines 4 structured components, typically over about a year: weekly individual therapy, a weekly skills-training group teaching 4 skill modules (mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness), between-session phone coaching for in-the-moment skill use during a crisis, and a therapist consultation team that supports the treating clinicians themselves. One foundational DBT concept patients are taught is "Wise Mind" — the integration of "Reasonable Mind" (logical, fact-based thinking) and "Emotion Mind" (feeling-driven thinking) into a balanced state that draws on both. Understanding this concept helps a pharmacist recognize and reinforce the skills language a patient in DBT is already using.
Mentalization-based therapy (MBT)
MBT helps patients build the capacity to accurately reflect on their own and others' mental states — thoughts, feelings, and intentions — which is thought to reduce the misinterpretation-driven interpersonal crises common in BPD. It is typically delivered as combined individual and group therapy over about 18 months. An 8-year follow-up of the original randomized trial found that patients who received partial-hospitalization MBT remained meaningfully better than those who received treatment as usual, even years after the structured treatment itself had ended, though general social functioning remained impaired in both groups.[12]
Schema-focused therapy
Identifies maladaptive early "schemas" or emotional "modes" (for example, an abandoned/abused child mode, an angry/impulsive child mode, a punitive-parent mode, and a detached-protector mode) and works to build a stable "healthy adult" mode able to manage them. In a head-to-head Dutch randomized trial, 3 years of schema-focused therapy outperformed transference-focused psychotherapy on BPD-specific and general psychopathology measures and on quality of life, with substantially lower treatment dropout.[13]
General Psychiatric Management (GPM) / structured clinical management
A less resource-intensive, generalist model combining case management, structured clinical support, and psychoeducation, without requiring specialized DBT/MBT/schema-therapy certification. Trial evidence shows it performs comparably to specialized therapies for many patients, making it a genuinely reasonable option — not a fallback of last resort — where specialized programs are not locally available.[4][12]
Crisis and safety planning
A written, collaboratively developed safety plan — personal warning signs, specific coping strategies, people and services to contact, and means restriction where relevant — is itself an active nonpharmacologic intervention, not paperwork. Review and update it regularly, and treat it as a living document the patient helps write, not one handed to them.
Stigma-aware, validating communication for pharmacy staff
BPD carries more clinician-level stigma than almost any other psychiatric diagnosis — language like "manipulative," "attention-seeking," or "difficult patient" is both inaccurate and actively harmful to care.[9] Practical guidance for every pharmacy interaction:
- Validate the emotion behind the behaviour, even when the behaviour itself cannot be accommodated — for example, "I can see you're in a lot of pain right now" rather than dismissing or arguing with the presentation.
- Maintain consistent, predictable boundaries — inconsistency between staff members (one being lenient, another strict, on the same request) can itself trigger dysregulation; agree on a shared approach as a team.
- Do not take angry or dismissive statements personally — these often reflect the disorder's core interpersonal instability in the moment, not an accurate judgment of pharmacy staff.
- Never withhold standard, safe pharmacy care as an implicit "consequence" for a difficult interaction.
- Treat every self-harm disclosure as a genuine clinical symptom requiring the pharmacy's own compassionate, structured escalation response (see Red Flags) — never as a nuisance or bid for attention.[9]
- Recognize splitting for what it is — a recognized symptom pattern (idealizing one staff member, devaluing another), not evidence that one staff member handled things correctly and another did not. Bring it to the team rather than personalizing or taking sides.
Special Populations
Pregnancy
Structured psychotherapy remains the preferred foundation of treatment throughout pregnancy and carries no reproductive risk. Avoid divalproex — a major teratogen associated with neural tube defects and neurodevelopmental impairment — and use topiramate only with real caution given an increased risk of oral clefts; confirm effective contraception before starting either in any patient of reproductive potential, and discuss this explicitly rather than assuming it has been covered elsewhere.[5] If pharmacotherapy is genuinely needed an SSRI for a comorbid depressive or anxiety disorder is generally preferred, following the same principles as the Depression and Anxiety Disorders chapters. The postpartum period carries a genuinely elevated risk of symptom exacerbation for BPD specifically — schedule closer follow-up and reassess safety proactively rather than waiting for the patient to raise concerns; any concern for infant safety is a red flag requiring urgent escalation (see Red Flags).
Breastfeeding
Sertraline and other standard-dose SSRIs are generally considered compatible with breastfeeding. Lamotrigine and divalproex are used with infant monitoring where clinically necessary. Antipsychotics (aripiprazole, olanzapine, quetiapine) require an individualized risk-benefit discussion; confirm current guidance for the specific agent before continuing use while breastfeeding.
Adolescents
BPD traits and patterns can be recognized, and DBT adapted specifically for adolescents (DBT-A) has real supporting evidence — dismissing this presentation as "just a phase" delays care that is more effective the earlier it starts. A formal personality disorder diagnosis in a minor should be made by a clinician with specific training in adolescent assessment, but the symptom pattern itself should prompt referral regardless of whether a formal diagnosis has yet been made.
Older adults
Impulsivity and behavioural dyscontrol often attenuate with age, though affective instability and chronic emptiness can persist. Polypharmacy risk is higher in this group given concurrent chronic-disease medication — actively reassess whether any ongoing psychotropic still has a clear, current target symptom rather than continuing it by default.
Comorbid substance use disorder
Present in roughly half of patients with BPD, comorbid substance use disorder complicates both psychotherapy engagement and self-harm risk. Integrated, concurrent treatment of both conditions together is preferred over treating one and deferring the other. Use particular caution with any medication carrying its own dependence or disinhibition risk (see benzodiazepines, above) in this specific overlap population.
Renal and hepatic impairment
Dose-adjust lamotrigine, topiramate, and quetiapine for reduced renal function, and use divalproex with caution and closer monitoring in hepatic impairment given its own hepatotoxicity risk. Aripiprazole and olanzapine generally require less renal adjustment but should still be used cautiously and at a lower starting dose in significant hepatic impairment. Confirm specifics against each drug's own Drug Database entry or current product monograph.
Monitoring & Follow-Up
- Ask directly and nonjudgmentally about self-harm and suicidal ideation at every relevant encounter — asking does not increase risk, and a direct question is far more useful than avoiding the topic out of discomfort.[6]
- Track engagement with structured psychotherapy specifically — early dropout is common in this population and is itself a clinically meaningful signal warranting outreach, not simply "noncompliance" to be noted and left unaddressed.
- For any pharmacotherapy started, confirm it still has an explicit target symptom and a defined reassessment date; discontinue promptly if that specific target has not clearly improved within a reasonable trial, rather than letting it continue indefinitely by default or adding a further agent on top.[5][2]
- Screen for and actively manage comorbid conditions (mood and anxiety disorders, eating disorders, substance use disorder) on an ongoing basis rather than attributing every new symptom to "the personality disorder."
- For divalproex: baseline and periodic liver function tests, CBC/platelets, and an explicit, repeated pregnancy-prevention discussion for anyone of reproductive potential.
- For any antipsychotic (aripiprazole, olanzapine, quetiapine), apply the same baseline and ongoing metabolic monitoring (weight, waist circumference, fasting glucose, lipids) used for any other antipsychotic — "low dose" does not exempt a patient from this monitoring.
- Reassess the overall diagnosis and formulation periodically rather than treating it as fixed — comorbidities evolve, and a substantial proportion of patients achieve sustained symptomatic remission over years; reinforce this realistic, hopeful trajectory with the patient directly rather than defaulting to chronic-illness framing.[8]
Common Errors to Avoid
- Using pejorative language — "manipulative," "attention-seeking," "difficult," or "borderline" used as an insult — in conversation or documentation; this is documented, harmful clinician-level stigma specific to this diagnosis.[9]
- Starting or continuing medication as the first or sole treatment instead of referring for structured, evidence-based psychotherapy.
- Reflexive polypharmacy — stacking multiple unproven psychotropic agents over time without a specific, time-boxed target symptom and an explicit plan to stop an ineffective one.
- Prescribing or continuing benzodiazepines routinely, despite the real disinhibition, paradoxical-aggression, and dependence risk in this specific population.
- Dismissing repeated self-harm disclosures as attention-seeking rather than treating every disclosure as a genuine clinical symptom warranting a structured, compassionate response.
- Assuming a single "true" account of a staff conflict when a patient describes classic splitting — bring it to the team rather than personalizing it or silently taking sides.
- Withholding standard, safe pharmacy care as an implicit "consequence" for a difficult interaction.
- Diagnosing bipolar disorder (or BPD) from the phrase "mood swings" alone, without assessing actual episode duration and interpersonal trigger pattern.[10]
- Missing an undertreated comorbidity (depression, anxiety, substance use disorder, eating disorder, PTSD) and attributing every new symptom to "the personality disorder."
- Prescribing divalproex to a patient of reproductive potential without an explicit teratogenicity and contraception discussion.
- Treating a clear adolescent BPD symptom pattern as "just typical teenage moodiness" and delaying referral, when earlier intervention is associated with a better long-term trajectory.
- Assuming the disorder is lifelong and untreatable — current long-term follow-up data show most patients achieve sustained symptomatic remission with appropriate treatment.[8]
Clinical Decision Algorithm
Drug Tables
No medication in this table is approved by Health Canada or the FDA for borderline personality disorder itself. Every class below is adjunctive only, reserved for a specific comorbid symptom cluster, and should be started with an explicit target symptom and reassessment date. Select any drug name to open its complete Pharmasist Drug Database page.
SSRIs — for a comorbid mood or anxiety disorder
Dosed and monitored exactly as in the Depression and Anxiety Disorders chapters. Treats the comorbidity; evidence for a BPD-specific mood-lability benefit alone is weak and inconsistent.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Fluoxetine | Initial: 10-20 mg PO each morning Maximum: 60-80 mg/day | GI upset, insomnia, sexual dysfunction, anxiety on initiation | Potent CYP2D6 inhibitor; contraindicated with an MAOI | Long half-life gives some self-tapering protection against a missed dose or abrupt discontinuation. |
| Sertraline | Initial: 50 mg PO once daily Maximum: 200 mg/day | GI upset, insomnia, sexual dysfunction, sweating | Contraindicated with an MAOI; caution with other serotonergic agents | A commonly preferred first SSRI given a comparatively favourable interaction profile. |
Mood stabilizers/anticonvulsants — for impulsivity, anger, or affective instability
Modest, low-certainty trial evidence for this specific symptom cluster; at least 1 large, more rigorous trial found no benefit for lamotrigine over placebo. Confirm effective contraception before starting any of these in a patient of reproductive potential.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Lamotrigine | Titration: Per product monograph, starting low and increasing gradually over several weeks | Rash (including rare Stevens-Johnson syndrome/toxic epidermal necrolysis), headache, dizziness, diplopia | Valproate substantially raises lamotrigine levels — requires a slower, lower-dose titration; carbamazepine lowers levels | Titrate very slowly per the product monograph specifically to reduce serious rash risk — do not accelerate titration to chase a faster response. |
| Divalproex (valproate) | Dosing: Per product monograph, with therapeutic drug monitoring | Weight gain, tremor, hepatotoxicity, thrombocytopenia, hyperammonemia | Increases lamotrigine levels; interacts with other hepatically metabolized drugs | Major teratogen — avoid in pregnancy and confirm effective contraception before starting in anyone of reproductive potential. |
| Topiramate | Titration: Per product monograph, starting low and increasing gradually | Cognitive slowing/word-finding difficulty, paresthesias, weight loss, nephrolithiasis risk | May reduce the efficacy of estrogen-containing contraceptives at higher doses | Increased oral cleft risk in pregnancy — use with real caution, and confirm effective contraception. |
Low-dose atypical antipsychotics — for transient cognitive-perceptual symptoms or severe affective instability
Modest short-term trial evidence. Apply the same baseline and ongoing metabolic monitoring (weight, waist circumference, fasting glucose, lipids) used for any other antipsychotic indication — a low dose does not exempt a patient from this monitoring.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Aripiprazole | Initial: Low dose per product monograph, titrated to the lowest effective dose | Akathisia, insomnia, headache, nausea | Additive QTc effects with other QTc-prolonging drugs; CYP2D6/3A4 interactions can raise or lower levels | Comparatively lower metabolic burden than olanzapine or quetiapine; generally the preferred first choice within this class. |
| Olanzapine | Initial: Low dose per product monograph | Substantial weight gain, dyslipidemia, sedation, metabolic syndrome risk | Additive sedation with other CNS depressants; smoking reduces levels via CYP1A2 induction | Trial evidence for this indication is mixed; the significant metabolic burden makes it a lower preference than aripiprazole. |
| Quetiapine | Initial: Low dose at bedtime per product monograph | Sedation, weight gain, orthostatic hypotension, metabolic effects | Additive sedation with other CNS depressants; CYP3A4 interactions affect levels | Sedation can help sleep, but sleep improvement alone is not itself a reason to continue if the target symptom cluster has not improved. |
Agents to avoid for routine use
Included to make the avoid guidance explicit and easy to find, not because these are recommended.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Clonazepam | Routine BPD use: Not recommended | Sedation, disinhibition, paradoxical aggression, dependence with regular use | Additive CNS depression with alcohol, opioids, or other sedatives | No BPD-specific role; real risk of worsening impulsivity/behavioural dyscontrol in this specific population. |
| Lorazepam | Routine BPD use: Not recommended | Sedation, disinhibition, paradoxical aggression, dependence with regular use | Additive CNS depression with alcohol, opioids, or other sedatives | No BPD-specific role; avoid routine or ongoing use given dependence and disinhibition risk. |
References
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) — American Psychiatric Association. Washington (DC): American Psychiatric Publishing; 2022
- Borderline personality disorder: recognition and management — National Institute for Health and Care Excellence (NICE), Clinical Guideline CG78. NICE Clinical Guideline CG78, published 28 January 2009, last reviewed 30 July 2024
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder — American Journal of Psychiatry, American Psychiatric Association (2nd edition). Am J Psychiatry 2024 (2nd ed.)
- Psychological therapies for people with borderline personality disorder — Cochrane Database of Systematic Reviews (Storebø OJ, Stoffers-Winterling JM, Völlm BA, et al.). Cochrane Database Syst Rev 2020;5:CD012955
- Pharmacological interventions for people with borderline personality disorder — Cochrane Database of Systematic Reviews (Stoffers-Winterling JM, Storebø OJ, Kongerslev MT, et al.). Cochrane Database Syst Rev 2022;11:CD012956
- Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction, and prevention — Journal of Personality Disorders (Black DW, Blum N, Pfohl B, Hale N). J Pers Disord 2004;18(3):226-239
- A biosocial developmental model of borderline personality: Elaborating and extending Linehan's theory — Psychological Bulletin (Crowell SE, Beauchaine TP, Linehan MM). Psychol Bull 2009;135(3):495-510
- Time to attainment of recovery from borderline personality disorder and stability of recovery: A 10-year prospective follow-up study — American Journal of Psychiatry (Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G). Am J Psychiatry 2010;167(6):663-667
- Borderline personality disorder, stigma, and treatment implications — Harvard Review of Psychiatry (Aviram RB, Brodsky BS, Stanley B). Harv Rev Psychiatry 2006;14(5):249-256
- Borderline personality disorder and bipolar disorder: what is the difference and why does it matter? — Journal of Nervous and Mental Disease (Paris J, Black DW). J Nerv Ment Dis 2015;203(1):3-7
- Distinguishing between ICD-11 complex post-traumatic stress disorder and borderline personality disorder: clinical guide and recommendations for future research — The British Journal of Psychiatry (Karatzias T, Bohus M, Shevlin M, Hyland P, Bisson JI, Roberts N, Cloitre M). Br J Psychiatry 2023;223(3):403-406
- 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual — American Journal of Psychiatry (Bateman A, Fonagy P). Am J Psychiatry 2008;165(5):631-638
- Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs transference-focused psychotherapy — Archives of General Psychiatry (Giesen-Bloo J, van Dyck R, Spinhoven P, et al.). Arch Gen Psychiatry 2006;63(6):649-658
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.